Figure 4.

Combined with carboplatin, 2DG reduces the tumor burden of TOV21G cell line xenografts. Luciferase-labelled TOV21G cells (2 × 10⁵) were injected intraperitoneally (i.p.) into female NSG mice, with treatment starting two weeks later with PBS (control), 2DG (50 mg/kg/week), carboplatin (10 mg/kg/week), or a combination 2DG and carboplatin. Bioluminescent tumor burden was measured weekly with mice sacrificed at day 37. (A) Left, representative bioluminescent images of mice. Luminescence signal is provided in radiance units (p/s/cm2/sr). Right, graph of bioluminescence signal. (B) Left, representative images of mesenteric membrane of mice harvested from each group, with tumor nodules indicated by white asterisks. Right, graph of tumor nodules ≥ 8 mm³. (C) Graph of ascites volume. (D) Graph of glycogen content of tumors. Results are presented as mean +/− SD. *, p ≤ 0.05; **, p ≤ 0.01.